Pascal Prigent, Genfit CEO
December 17, 2021 06:37 AM ESTUpdated December 17, 10:11 PM
Deals

Ipsen fronts $136M to bag Gen­fit's once-failed NASH drug, bet­ting on its po­ten­tial in rare liv­er con­di­tion

Amber Tong

Some­body be­lieves in elafi­bra­nor af­ter all.

The drug, which had been con­sid­ered a bright prospect in the fail­ure-prone but high­ly lu­cra­tive race to treat …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times